This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
Protocol Amendment History
12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-03-26; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting2026-01-13